Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment.

Oncol Ther · 2018 · PMC7360016 · PMID 32700135

Europe PMC DOI

hedged sentences

0.0120

closest p · 0.2× alpha

0.0120

boldest claim

The sentences

did not reach statistical significancep = 0.012actually significant

Even though this decrease did not reach statistical significance in the whole cohort, subgroup analysis showed that the decreases were significant in patients with high VEGFR2 expression (93% vs. 67.7%, p = 0.012), or positive kinase-insert domain-containing receptor expression (94.4% vs. 47.3%, p = 0.002) [ 13 ].

also in 111,027 other papers

showed a trendno p-value reported

It also showed a trend in improving PFS and ORR, but not OS.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.